Market Closed - Euronext Paris 11:35:22 2024-04-19 am EDT After market 03:59:58 pm
99.55 EUR +0.56% Intraday chart for bioMérieux 99.35 -0.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stifel Reaffirms bioMérieux at Buy, Lifts PT MT
BIOMÉRIEUX : Stifel raises target price CF
Invest Securities Lifts BioMérieux PT, Maintains at Buy MT
Oddo BHF Raises bioMérieux PT, Affirms Neutral Recommendation MT
BIOMÉRIEUX : Oddo BHF raises its target price CF
BIOMÉRIEUX : Invest Securities raises its target CF
BIOMERIEUX : A strong start to 2024 Alphavalue
BioMérieux: hailed for its business review and targets CF
U.S. Futures Mixed, European Stocks Lower Ahead of U.S. Inflation Data This Week DJ
Transcript : BioMérieux S.A. - Analyst/Investor Day
BioMérieux: targets set for 2024-28 CF
BioMérieux: growth of over 6% in Q1 CF
BioMérieux: food safety initiative CF
BioMérieux: FDA approval for multiplex PCR test CF
Berenberg Upgrades BioMérieux to Buy from Hold, Lifts PT MT
BIOMÉRIEUX : Berenberg upgrades its recommendation to 'buy CF
BioMérieux: Invest Securities reiterates its opinion CF
Invest Securities Keeps BioMérieux at Buy, Reduces PT MT
BIOMÉRIEUX : Invest Securities remains positive, reduces its target CF
BIOMERIEUX : Good end to 2023; routine testing dynamics remain intact Alphavalue
Transcript : BioMérieux S.A., 2023 Earnings Call, Mar 14, 2024
BioMérieux S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioMérieux: RNPG down 21% in 2023 CF
SpinChip Diagnostics AS announced that it has received NOK 115 million in funding from bioMérieux S.A. CI
BioMérieux appoints two new members to its Executive Committee CF
Chart bioMérieux
More charts
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
99 EUR
Average target price
110.5 EUR
Spread / Average Target
+11.62%
Consensus
  1. Stock Market
  2. Equities
  3. BIM Stock
  4. News bioMérieux
  5. Qiagen, bioMérieux in Merger Talks to Create Medical Diagnostics Behemoth